Outcomes of Heart Transplantation from Hepatitis C Virus Positive Donors
National data demonstrate that increasing opportunities exist for organ donation among hepatitis C virus (HCV) infected individuals.
We describe our experience with immediate post-transplant use of GLE/PIB in relation to sustained virologic response (SVR) based on route of administration.
Since the highly effective Direct-Acting Antiviral (DAA) therapies have been available for treatment of HCV, transplant centers have begun using organs from HCV infected donors followed by treatment with DAAs. Epidemiological studies have shown that HCV may be associated with an increase atherosclerosis and it has been hypothesized that this is caused by activation of an immunological or inflammatory response. HCV infection of endothelial cells may promote endothelial dysfunction and early atherogenesis.
We present the first described case of DAA treatment failure in a patient who received an HCV donor, nucleic acid testing (NAT) positive heart.
Hepatitis C (HCV) organs have been increasingly utilized in solid organ transplantation since the advent of curative direct acting anti-viral (DAA) therapy. Despite the adoption of this strategy, many unanswered questions remain regarding the management of immunosuppression. In two small case series of liver transplant recipients, tacrolimus concentrations have been shown to decrease with clearance of HCV viremia. We seek to describe our experience and clinical implications in our cardiac transplant population.
We report the incidence of CAV in heart transplant recipients from HCV viremic donors (nucleic amplification test positive; NAT+) compared to non-HCV infected donors (NAT-).
Passive transmission of hepatitis C (HCV) viremia from actively infected donors to uninfected recipients at the time of heart transplantation may modulate response to alloantigens and risk of allograft rejection. We evaluated the one-year incidence of acute cellular rejection (ACR) in patients transplanted from nucleic amplification testing positive (NAT+) HCV donors compared to those from NAT negative (NAT-) donors.
Thoracic organ transplantation from Hepatitis C (HCV) viremic donors is a promising strategy due to curative therapies for HCV. Currently, there is no consensus on the best time to initiate HCV therapy relative to time of transplantation. We assessed the difference in magnitude of viremia and time to clearance in recipients of heart (HT) and lung (LT) transplant, based on timing of starting antiviral HCV therapy.
This study is an updated analysis of outcomes after HCV+ heart transplantation in the United States.
We sought to compare survival outcomes of lung transplant (LTx) patients after receiving donor lungs with increased or standard risk for exposure to human immunodeficiency (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).
We report the utilization and outcomes of transplantation of HCV NAT positive (HCV NAT+) hearts recorded in the United Network for Organ Sharing (UNOS) database.